Aethoxysklerol 0.5%

Country: Jordan

Language: English

Source: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

Active ingredient:

Lauromacrogol 400 (Polidocanol) 0.5 %

Available from:

مستودع ادوية المتنبي - Almutanabbe Drug Store

ATC code:

C05BB02

INN (International Name):

Lauromacrogol 400 (Polidocanol) 0.5 %

Dosage:

0.5%

Units in package:

5 Amp X 2ml

Manufactured by:

Siegfried Hameln GmbH/GERMANY (المانيا)

Patient Information leaflet

PACKAGE LEAFLET
AETHOXYSKLEROL
®
0.5%
Active
substance:
lauromacrogol
400
(polidocanol)
Solution for intravenous injection, used for the
obliteration of varicose veins
DEAR PATIENT,
AETHOXYSKLEROL 0.5% IS ADMINISTERED BY A
DOCTOR.
NEVERTHELESS,
PLEASE
READ
THE
FOLLOWING LEAFLET CAREFULLY BEFORE TREATMENT,
BECAUSE IT CONTAINS IMPORTANT INFORMATION
ABOUT WHAT YOU SHOULD OBSERVE DURING USE OF
THIS MEDICINE.
– Keep this leaflet. You may need to read it again.
– If you have any further questions, please ask
your doctor or your pharmacist.
– If any of the side effects gets serious, or if you
notice any side effects not listed in this leaflet,
please tell your doctor or pharmacist.
IN THIS LEAFLET:
1.  What Aethoxysklerol 0.5% is and what it is
used for
2.  Before you use Aethoxysklerol 0.5%
3.  How to use Aethoxysklerol 0.5%
4.  Possible side effects
5.  How to store Aethoxysklerol 0.5%
6.  Further information
1.  WHAT AETHOXYSKLEROL 0.5% IS AND WHAT
IT IS USED FOR
Different concentrations of Aethoxysklerol are
required, depending on the size of the varices
(varicose veins) to be sclerosed.
Aethoxysklerol 0.5% is used for sclerotherapy of
spider veins and central veins of spider veins.
2.  BEFORE YOU USE AETHOXYSKLEROL 0.5%
DO NOT USE AETHOXYSKLEROL 0.5%
– in patients with known allergy to lauromacrogol
400
(polidocanol)
or
any
of
the
other
ingredients of Aethoxysklerol
– in bedridden patients or patients who are
unable to walk
– in patients with severe, arterial blood flow
problems (arterial occlusive disease Fontaine
stage III and IV)
– in patients with a blood vessel blockage due to
a local or detached blood clot (thromboembolic
diseases)
– in patients at high risk of blood vessel blockage
(thrombosis), e.g. patients born with a tendency
for blood clots or with several risk factors, such
as the use of hormonal contraceptives (e.g. the
Pill) or hormone replacement therapy, being
overweight,
smoking,
extended
periods
of
immobility, etc.
– in
patients
with
acute
severe
disease
(especi